Huntington’s disease affects roughly 4 to 9 people per 100,000 in most Western populations, making it rare enough to qualify for orphan disease status from the FDA. To put that in perspective, about 1 in 2,500 people of European descent carry the gene mutation that will cause the disease if they live a normal lifespan. It’s uncommon, but not as vanishingly rare as many other genetic disorders.
Prevalence by the Numbers
In Europe and the United States, Huntington’s disease shows up at a rate of 4 to 9 per 100,000 people. That translates to roughly 30,000 to 40,000 affected individuals in the U.S. at any given time, with many more carrying the gene but not yet showing symptoms. Population-based research from Northern Scotland found that 1 in 400 people carry some form of the relevant gene expansion, though most of those expansions fall in ranges that may never produce symptoms or only carry partial risk.
The disease is far less common in East Asian and African populations, where prevalence drops to 0.1 to 1 per 100,000, less than one-tenth the rate seen in Caucasian groups. Even within Europe, there are outliers: Finland reports only about 0.5 per 100,000, while Belgium sits around 1.6 per 100,000. The reasons for these differences trace back to genetics. The specific DNA pattern that predisposes people to Huntington’s is more common on certain ancestral chromosomes found primarily in European-descended populations.
One Region With Extraordinarily High Rates
The Lake Maracaibo region of Venezuela has the highest known concentration of Huntington’s disease anywhere in the world, with roughly 700 cases per 100,000 people. That’s nearly 100 times the typical Western rate. The cluster traces back to a single ancestor who carried the mutation several generations ago, and the relatively isolated community around the lake allowed it to spread widely. This population has been central to Huntington’s research since the 1970s and played a key role in the original discovery of the gene responsible for the disease in 1993.
How the Genetics Work
Huntington’s disease is caused by an abnormal stretch of repeating DNA in a single gene. Everyone has this gene, and everyone has some repeats in it. The question is how many. With 26 or fewer repeats, you’re in the normal range and will not develop the disease. Between 27 and 35 repeats, you still won’t develop symptoms yourself, but the repeat count can expand when passed to children, potentially pushing them into a risk range.
At 36 to 39 repeats, risk becomes real but not certain. Some people in this range develop Huntington’s, others don’t. At 40 repeats or more, the disease will develop if you live a normal lifespan. This is called full penetrance, meaning the gene guarantees the outcome. The higher the repeat count, the earlier symptoms tend to appear.
Huntington’s is autosomal dominant, so you only need one copy of the expanded gene to be affected. If one parent carries it, each child has a 50% chance of inheriting it. In rare cases, someone develops Huntington’s without any known family history, typically because a parent’s borderline repeat count expanded during reproduction.
Most At-Risk People Don’t Get Tested
Predictive genetic testing has been available since the mid-1990s, allowing people with an affected parent to find out whether they carry the expansion before any symptoms appear. Despite this, only about 12 to 15% of people at 50% risk choose to get tested. The reasons are deeply personal. A positive result means a certainty of future decline with no current cure, and many people prefer to live without that knowledge. Others want the information for family planning or simply to resolve the uncertainty.
This low testing rate also means that prevalence figures likely undercount the true number of gene carriers in the population. Many people who carry the expansion will never be counted in medical statistics because they were never tested or diagnosed.
What Happens After Symptoms Start
Symptoms typically appear between ages 30 and 50, though the range is wide. The disease affects movement, cognition, and behavior, often starting with subtle changes like irritability, difficulty concentrating, or slight involuntary movements. These early signs can go unrecognized for years.
The disease progresses through roughly nine stages. Motor and cognitive problems show up early, in the first two stages, but functional ability (things like holding a job and managing daily tasks) tends to hold relatively steady until around stage four. Those first two stages can span about 16 years combined, which means many people live with the disease for a long stretch before reaching severe disability. The later stages bring significant decline across all domains, including cognition, movement, and the ability to perform basic self-care. After symptoms first appear, most people live another 15 to 20 years.
About 5% of all cases are classified as juvenile Huntington’s disease, meaning symptoms begin before age 20. Juvenile cases tend to involve higher repeat counts (often inherited from the father’s side, where repeats are more likely to expand) and progress differently, with seizures and rigidity being more prominent than the involuntary movements seen in adults.
Rare, but Not Ultra-Rare
In the world of genetic diseases, Huntington’s occupies a middle ground. It’s rare enough to receive orphan drug designation from the FDA, which applies to conditions affecting fewer than 200,000 Americans. But it’s common enough that most neurologists will see cases during their careers, and most people know someone who has been touched by it. For comparison, cystic fibrosis affects about 1 in 3,500 births in Western populations, putting it in a similar ballpark. Conditions like Tay-Sachs disease (roughly 1 in 100,000 births) or Pompe disease (1 in 40,000) are considerably rarer.
The practical reality for families is shaped less by population statistics and more by the 50/50 coin flip of inheritance. If you have an affected parent, Huntington’s disease isn’t rare at all. It’s the defining medical reality of your family, with each child facing even odds of carrying the same expansion.